GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy

GSK said on Monday its experimental chronic hepatitis B drug received its first global approval in Japan, and a key ​cancer therapy was granted a priority U.S. regulatory review ‌as a possible rectal ...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。